{"id":9784,"date":"2009-02-03T00:00:00","date_gmt":"2009-02-03T00:00:00","guid":{"rendered":""},"modified":"-0001-11-30T00:00:00","modified_gmt":"-0001-11-30T04:00:00","slug":"eastbourne-proposes-amylin-directors-backs-icahn","status":"publish","type":"post","link":"https:\/\/hedgeco.net\/news\/02\/2009\/eastbourne-proposes-amylin-directors-backs-icahn.html","title":{"rendered":"Eastbourne Proposes Amylin Directors, Backs Icahn"},"content":{"rendered":"<p>Bloomberg &#8211; Hedge fund Eastbourne Capital Management LLC nominated five directors to the board of Amylin Pharmaceuticals Inc. and is supporting a slate put forward by investor Carl Icahn, after it &ldquo;lost confidence&rdquo; in leadership of the maker of the Byetta diabetes drug. <\/p>\n<p>Eastbourne, which owns 12.5 percent of San Diego-based Amylin, said in a letter to management yesterday that the company&rsquo;s board needs to be &ldquo;significantly strengthened&rdquo; after the stock fell almost 80 percent since Oct. 5, 2007. In November, Eastbourne said it was talking with Amylin about options including &ldquo;a possible acquisition by a third party.&rdquo; <\/p>\n<p><a href=\"http:\/\/www.hedgeco.net\/news\/news_land.php?i=http:\/\/www.bloomberg.com\/apps\/news?pid=20601202&#038;sid=acGmRVOdgT5w&#038;refer=healthcare\" target=\"_blank\"><strong>Read Complete Article<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bloomberg &#8211; Hedge fund Eastbourne Capital Management LLC nominated five directors to the board of Amylin Pharmaceuticals Inc. and is supporting a slate put forward by investor Carl Icahn, after it &ldquo;lost confidence&rdquo; in leadership of the maker of the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[3491,6838,6840,3314,3813,4712,6842,6839,4650,3308,6841,6008,6843,510,336,47],"class_list":["post-9784","post","type-post","status-publish","format-standard","hentry","category-syndicated","tag-acquisition","tag-amylin-pharmaceuticals-inc","tag-byetta","tag-capital-management-llc","tag-carl-icahn","tag-confidence","tag-diabetes","tag-diabetes-drug","tag-investor","tag-leadership","tag-oct-5","tag-s-board","tag-san-diego","tag-slate","tag-stock","tag-third-party"],"_links":{"self":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/posts\/9784","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/comments?post=9784"}],"version-history":[{"count":0,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/posts\/9784\/revisions"}],"wp:attachment":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/media?parent=9784"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/categories?post=9784"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/tags?post=9784"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}